Pills masthead

Lannett Announces Multiple Product Launches

PHILADELPHIA, July 23, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it launched four products in June 2018, bringing to seven the total number of products launched since January 1, 2018. 

Lannett Logo (PRNewsFoto/Lannett Company, Inc.)

The June product launches include Diclofenac Sodium ER Tablets, Levofloxacin Oral Solution, Memantine Hydrochloride Tablets and Metolazone Tablets.  Total U.S. sales of the combined products were nearly $100 million for the 12 months ended May 2018, according to IMS.

"With these four products, we have commenced seven launches since the beginning of the current calendar year," said Tim Crew, chief executive officer of Lannett.  "I'm pleased with the progress that our cross-functional teams are making with regard to launching the commercially ready products in our pipeline.  We expect to commence marketing several additional products shortly and a number of others over the course of fiscal 2019." 

About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.  For more information, visit the company's website at www.lannett.com.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance.  Any such statement, including, but not limited to, successfully commercializing Diclofenac Sodium ER Tablets, Levofloxacin Oral Solution, Memantine Hydrochloride Tablets and Metolazone Tablets, and the planned launches of other products, whether expressed or implied, is subject to market and other conditions, and subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the risk factors discussed in the Company's Form 10-K and other documents filed with the SEC from time to time, including the prospectus supplement related to the proposed offering to be filed with the SEC.  These forward-looking statements represent the Company's judgment as of the date of this news release.  The Company disclaims any intent or obligation to update these forward-looking statements.



Robert Jaffe


Robert Jaffe Co., LLC


(424) 288-4098



SOURCE Lannett Company, Inc.

Price Data